Oramed creates cutting edge medical solutions, transforming injected medicines into oral medicines. Twenty years of intense research preceded the company’s creation. Once launched, the company sprinted ahead, testing a flagship concept designed to enable diabetics to receive insulin orally. A successful meeting with the FDA followed. Today, their proprietary protein delivery method serves as a template for methodologies that will eventually make injected medicines outdated. One farsighted company willing to take a stake in Oramed’s groundbreaking technology is Altium Capital, launched in 2018. Its Founder, entrepreneurial dynamo, Jacob Gottlieb, believes now is an explosive time in the medical field, with new technologies emerging regularly.
Possessed with a passionate partisanship for both medicine and finance, Gottlieb began his self-tutelage while still a minor, scouring tomes written by Warren Buffet. He went on to achieve a magna cum laude BA in Economics from Brown University and an MD from New York Medical University. Post medical school Jacob Gottlieb began an internship in internal medicine, which he ultimately set aside in favor of a career in investment.
As a doctor, Jacob Gottlieb has never stopped caring about patient care. As an investment specialist he’s made it a personal mission to sass out companies that are taking healthcare to the next level. That’s the focus of Altium Capital. Before the inception of Altium Capital, Gottlieb was a stock portfolio manager known for his impressive yields at Balyasny Asset Management. From there, he partnered with a group of like-minded entrepreneurs and started the hedge fund, Visium. Throughout his growth as a financier, Gottlieb remained interested in finding forward-seeking medical companies. Besides that first 5.61% stake in Oramed, Altium has earmarked other medical companies for investment, including Oragenics and Amarin, which are proceeding in unprecedented ways in the fields of cardiovascular medicine and biotherapeutics.